Sovereign AI Platform for Drug Discovery and Virtual Screening
Try VigyanLLM Free →VigyanLLM's AI drug discovery platform provides automated virtual screening and binding affinity prediction for GPU-accelerated research. Runs entirely on-premises via Docker deployment with no data egress.
Consensus Docking for Reliable Hit Identification
Single-engine docking can produce misleading results due to scoring function biases. VigyanLLM's consensus pipeline runs three docking engines in parallel, cross-validates binding poses using RMSD clustering, and reports consensus scores that are more reliable than any individual engine. This approach significantly reduces false-positive rates in hit identification campaigns, saving time and resources in downstream validation.
End-to-End Drug Discovery Workflow
From target identification (gene expression analysis) to structure prediction (protein folding) to compound screening (molecular docking) to assay design (primer/probe design for target validation) — VigyanLLM covers the complete early-stage drug discovery pipeline within a single platform. No file format conversions, no tool switching, no data transfer between separate applications.
Frequently Asked Questions: AI drug discovery platform
Can VigyanLLM be used for drug discovery?
Yes. VigyanLLM provides a complete early-stage drug discovery toolkit: protein structure prediction for drug targets, multi-engine molecular docking for binding affinity prediction, virtual screening of compound libraries with consensus scoring, and integrated analysis across your research pipeline. The platform's sovereign on-premise architecture ensures your compound libraries and target data remain within your secure infrastructure.
Part of VigyanLLM Drug Discovery Hub — Explore all tools and resources for drug discovery.